The FERD3L antibody targets the FERD3L (FERM and PDZ Domain Containing 3L) protein, a less characterized member of the FERM domain-containing protein family. FERM domains are known to mediate interactions between membrane-associated proteins and the cytoskeleton, playing roles in cell adhesion, signaling, and structural organization. FERD3L is hypothesized to function similarly, potentially regulating cellular processes like polarity, membrane-cytoskeleton linkage, or signal transduction pathways. Its PDZ domain suggests involvement in protein-protein interactions, possibly scaffolding multiprotein complexes. Despite limited direct studies on FERD3L, related FERM proteins (e.g., ezrin, radixin, moesin) are well-documented in cancer metastasis, immune response, and neurological disorders, implying potential relevance in these areas. The FERD3L antibody is primarily used in research to detect and localize the protein in tissues or cultured cells, aiding in elucidating its expression patterns and biological roles. Emerging interest links FERD3L to diseases such as cancers or neurodevelopmental disorders, though mechanistic insights remain sparse. Commercial antibodies are typically validated for specificity in applications like Western blotting, immunohistochemistry, or immunofluorescence. Further studies are needed to define FERD3L’s precise functions and therapeutic potential.